...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study
【24h】

Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study

机译：具有低旋转病毒胃肠炎相关死亡率的国家对RotaVirus接种国家免疫计划的成本效益分析：韩国研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq~R; RV5) and attenuated human strain originated monovalent vaccine (Rotarix~R; RVl), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVsin the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RVl and RVS, respectively. The introduction of RVl and RVS can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RVl and 30,081 USD per DALY averted for RV S. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 x gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective.
机译：RotaVirus是韩国年龄5年龄小的儿童严重胃肠炎的主要原因。两个轮状病毒疫苗（RVS），五价人牛重配疫苗（Rotateq〜R; RV5）和减毒的人菌株发起的一价疫苗（rotarix〜R; RVL），可用于自2007年以来的自愿疫苗接种分别为2008年。然而，部分原因在国家免疫计划（NIP）中不包括，部分原因是低相关性死亡率。我们评估了RV的成本效益，以协助韩国筹集尼克筹集尼克效力的决策过程。使用透明年龄结构静态队列模型，我们模拟了2018至2027年韩国儿童十个年生育队列的体验。模型输入包括RotaVirus胃肠炎（RVGE）发病率和死亡率，RVGE治疗成本，疫苗覆盖率和及时性，和疫苗有效和价格。与无疫苗接种相比，辊隙的增量成本分别为59,662,738美元，用于RVL和RVS的152,444,379美元。 RVL和RV的引入可以防止4799个残疾调整后的终身年（DALYS）和5068个DALYS。从社会角度来看，采用RV与镊子的增量成本效益比率（逆转录者）每DALY为RVL的12,432美元，每Daly为RV S避免30,081美元。两者的反态的加权平均值使用当前自愿用作重量的每种疫苗的市场份额计算的疫苗为每达利21,698美元。估计的签年低于每人的国内生产总值1次（30,000美元），这一直是韩国卫生保健技术评估的常用意愿须为，这表明将RVS引入NIP将是具有成本效益的。

著录项

  • 来源
    《Vaccine》 |2019年第35期|共9页
  • 作者

    Hankil Lee; Seon Young Park; Andrew Clark;

  • 作者单位

    College of Pharmacy Yonsei Institute of Pharmaceutical Sciences Yonsei University Incheon South Korea;

    Department of Pharmaceutical Medicine and Regulatory Sciences Colleges of Medicine and Pharmacy Yonsei University Incheon South Korea;

    London School of Hygiene and Tropical Medicine Keppel Street London United Kingdom;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学免疫学;
  • 关键词

    Cost-effectiveness; Enteritis; Rotavirus; South Korea; Vaccination;

    机译：成本效益;肠炎;轮状病毒;韩国;疫苗接种;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号